Related Experiment Video
Updated: Jun 14, 2026
09:07
Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
Published on: May 27, 2015
Increased leukotriene E4 excretion in systemic mastocytosis
1Division of Allergic Diseases, Mayo Clinic, 200 SW 1st Street, Rochester, MN 55905, USA. butterfield.joseph@mayo.edu
Prostaglandins & Other Lipid Mediators
|April 13, 2010
Summary
Urinary levels of cysteinyl leukotrienes (LTE4) are significantly elevated in patients with systemic mastocytosis. This finding suggests LTE4 may contribute to the symptoms experienced by individuals with this mast cell disorder.
Area of Science:
- Biochemistry
- Immunology
- Hematology
Background:
- Cysteinyl leukotrienes (LTE4) are inflammatory mediators produced by various immune cells.
- Systemic mastocytosis is characterized by an abnormal increase in mast cells.
- LTE4 levels have not been previously reported in systemic mastocytosis.
Purpose of the Study:
- To investigate urinary LTE4 levels in patients with systemic mastocytosis.
- To determine if LTE4 excretion correlates with disease activity or other biomarkers.
Main Methods:
- Urinary LTE4 was measured using a commercial enzyme immunoassay kit.
- Patients were diagnosed with systemic mastocytosis based on World Health Organization criteria.
- Comparison was made between systemic mastocytosis patients and a control group with mast cell-related symptoms.
Main Results:
- Patients with systemic mastocytosis showed significantly increased urinary LTE4 excretion compared to controls (P=.01).
- Elevated LTE4 levels were observed regardless of whether expressed per gram of creatinine or per 24 hours.
- A moderate correlation was found between LTE4 and N-methyl histamine and serum tryptase, but not 11beta-prostaglandin F(2alpha).
Conclusions:
- Urinary LTE4 excretion is elevated in patients with systemic mastocytosis.
- Increased LTE4 may play a role in the pathogenesis of clinical symptoms in systemic mastocytosis.
- LTE4 could serve as a potential biomarker for systemic mastocytosis.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: